- Previous Close
0.0001 - Open
0.0001 - Bid --
- Ask --
- Day's Range
0.0001 - 0.0001 - 52 Week Range
0.0000 - 0.0002 - Volume
30,000 - Avg. Volume
0 - Market Cap (intraday)
1,837 - Beta (5Y Monthly) 45.42
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0220 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
WayPoint Biomedical Holdings, Inc., through its wholly owned subsidiary, WayPoint Biomedical, Inc., engages in the development and marketing of diagnostic tests and devices for screening and monitoring human health, fitness, and environment. It offers a drink spiking test, the Drink Detective, used to detect date rape drugs, including Ketamine, GHB, and Benzodiazapines; and Health Essist tests for cocaine and marijuana detection. The company also develops and commercializes test kits for detection against possible explosive devices, biowarfare/bioterrorism agents, and the detection of weapons of mass destruction. In addition, it provides Frontline Explosive Test Kit for the detection of explosive residues. The company offers its products to the over-the-counter diagnostic self-testing, the diagnostic point of care, and the homeland security and defense markets. WayPoint Biomedical Holdings was founded in 2004 and is based in Huntington Beach, California.
--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: WYPH
View MorePerformance Overview: WYPH
Trailing total returns as of 12/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WYPH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WYPH
View MoreValuation Measures
Market Cap
1.84k
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
33.24k
Net Income Avi to Common (ttm)
-806.27k
Diluted EPS (ttm)
-0.0220
Balance Sheet and Cash Flow
Total Cash (mrq)
2.47k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--